ArticleFrontiers in immunology2026
Case Report: Successful telitacicept treatment for IgA nephropathy with stage 4 chronic kidney disease and acute renal failure.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoglobulin A nephropathy (IgAN) is one of the most common forms of primary glomerulonephritis and can lead to renal failure requiring renal replacement therapy via dialysis. Current research indicates that telitacicept, an APRIL and BAFF inhibitor, has shown promise as a therapeutic option for IgAN patients with an estimated glomerular filtration rate (eGFR) over 30 mL/min/1.73 m². However, the efficacy of telitacicept in slowing the deterioration of kidney function, especially in individuals with stage 4 chronic kidney disease (CKD) and advancing IgAN, has yet to be documented. We present a 47-year-old male with stage 4 CKD, complicated by acute kidney injury and diagnosed with IgAN via biopsy, who was initially treated with 240 mg of telitacicept for 6 months, then transitioned to a gradual reduction and maintenance therapy for 12 months. After treatment, the proteinuria decreased from 2.82g/day to 0.60g/day. The eGFR gradually increased, improving from 26.95 to 35.69 mL/min/1.73 m² over 18 months. Serum albumin levels increased steadily, while hematuria gradually declined. Immunoglobulins and lymphocytes exhibited a decreasing pattern during treatment, with no notable rise in inflammatory markers. Furthermore, no infections or other adverse events were observed. This case shows the potential for telitacicept to be applied beyond its approved indications. This emphasizes the importance of conducting more research on individuals with advanced chronic kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.